



MPS PHARMAA LIMITED
(FORMERLY ADVIK LABORATORIES LIMITED)

Dated: 07/10/2023

To,
The Manager (Listing),
BSE Limited,
1st Floor, P. J. Towers,
Dalal Street,
Mumbai – 400001

Subject: Statement of Investor Complaints for the quarter ended 30th September, 2023

Ref: BSE Scrip Code– 531686; ASE Scrip Code– 01636 (ADVIK LABO)

Dear Sir,

As per the requirements of Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herein below the Statement of Investor Complaints for the quarter ended 30th September, 2023 for your kind perusal:

Number of Investor Complaints pending at the beginning of quarter ending on 30 th September, 2023, i.e. on 01 st July, 2023	Number of Investor Complaints received during the quarter ending on 30 th September, 2023, i.e. from 01 st July, 2023 to 30 th September, 2023	Number of Investor Complaints disposed of during the quarter ending 30 th September, 2023, i.e. from 01 st July, 2023 to 30 th September, 2023	Number of Investor Complaints remaining unresolved at the end of the quarter, i.e. on 30 th September, 2023
Nil	Nil	Nil	Nil

This is for your information and records please.

Thanking You.

Yours Faithfully,
For MPS Pharmaa Limited
(Formerly known as Advik Laboratories Limited)

Pooja Chuni
Company Secretary

CC:

The Manager (Listing)
Ahmedabad Stock Exchange Ltd.,
1st Floor, Kamdhenu Complex,
Opp. Sahajanand College, Panjarapole,
Ambawadi, Ahmedabad - 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, Fax: 011-43571047

Regd. Office & Factory: 138. ROZ-KaMeoIndustrial Area, Sohna - 122103 (Distt.Mewat), Haryana
Phones: 0124-2362471 Email:info@mpspharmaa.com Website: www.mpspharmaa.com